Pharmaceutical

NMPA approves Astellas’ PADCEV for advanced urothelial cancer

China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved Astellas’ PADCEV (enfortumab vedotin).

Aug 21, 2024 - 04:00
NMPA approves Astellas’ PADCEV for advanced urothelial cancer
China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved Astellas’ PADCEV (enfortumab vedotin).
Read the original article

Tags:

Previous Article

Colombia’s president signs law to strengthen pharmaceutical sector

Next Article

Homemade Hair Growth Shampoo

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NICE supports Theramex’s Eladynos for post-menopause osteoporosis

NICE supports Theramex’s Eladynos for post-menopause os...

Aug 11, 2024

Accolade beats analyst estimates, Teladoc’s optimism, and more JPM health tech news

Accolade beats analyst estimates, Teladoc’s optimism, a...

Jan 12, 2024

Cancer drug shortage eases slightly, but it’s still ‘living from paycheck to paycheck’

Cancer drug shortage eases slightly, but it’s still ‘li...

Oct 6, 2023